Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with Viral hepatitis-associated steatosis

World Journal of Gastroenterology

Volumn 21, Issue 46, 2015, Pages 12989-12995

  Haga, Yuki ^a   Kanda, Tatsuo ^a   Sasaki, Reina ^a   Nakamura, Masato ^a   Nakamoto, Shingo ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Non alcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL MARKER; DIRECT ANTIVIRAL AGENT; LAMIVUDINE; NUCLEOTIDE; PEGINTERFERON ALPHA2A; UNCLASSIFIED DRUG;

CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; DYSLIPIDEMIA; FATTY LIVER; HEPATITIS C; IMAGE ANALYSIS; LIVER BIOPSY; LIVER CIRRHOSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; REVIEW; VIRAL HEPATITIS ASSOCIATED STEATOSIS; ANIMAL; BLOOD; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMAN; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; BIOMARKERS; FATTY LIVER; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RISK FACTORS;

EID: 84950263082     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i46.12989     Document Type: Review

References (56)

1. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-384 [PMID: 20494470 DOI: 10.1016/j.jhep. 2010.04.008]
2. Polyzos SA, Mantzoros CS. Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism 2014;63:161-167 [PMID: 24290839 DOI: 10.1016/j.metabol.2013.10.010]
3. Yasui K, Harano Y, Mitsuyoshi H, Tsuji K, Endo M, Nakajima T, Minami M, Itoh Y, Zen Y, Nakanuma Y, Yoshikawa T, Okanoue T. Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus. J Gastroenterol 2010;45:95-104 [PMID: 19789836 DOI: 10.1007/s00535-009-0133-8]
4. Tsuzura H, Genda T, Sato S, Hirano K, Kanemitsu Y, Narita Y, Kikuchi T, Iijima K, Wada R, Ichida T. Association of visceral obesity with high viral load and histological findings in elderly patients with genotype 1 chronic hepatitis C. Intern Med 2013;52:1665-1673 [PMID: 23903497 DOI: 10.2169/internalmedicine.52.9430]
5. Hwang SJ, Luo JC, Chu CW, Lai CR, Lu CL, Tsay SH, Wu JC, Chang FY, Lee SD. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol 2001;16:190-195 [PMID: 11207900 DOI: 10.1046/j.1440-1746.2001.02407.x]
6. Jian Wu Y, Shu Chen L, Gui Qiang W. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver Int 2006;26:166-172 [PMID: 16448454 DOI: 10.1111/j.1478-3231.2005.01219.x]
7. Li JF, Qu F, Zheng SJ, Wu HL, Liu M, Liu S, Ren Y, Ren F, Chen Y, Duan ZP, Zhang JL. Elevated plasma sphingomyelin (d18:1/22:0) is closely related to hepatic steatosis in patients with chronic hepatitis C virus infection. Eur J Clin Microbiol Infect Dis 2014;33:1725-1732 [PMID: 24810965 DOI: 10.1007/s10096-014-2123-x]
8. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47 [PMID: 10847128 DOI: 10.1046/j.1365-2893.1999.6120139.x]
9. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-1745 [PMID: 9392700 DOI: 10.1056/NEJM199712113372406]
10. Yoneda M, Yamane K, Jitsuiki K, Nakanishi S, Kamei N, Watanabe H, Kohno N. Prevalence of metabolic syndrome compared between native Japanese and Japanese-Americans. Diabetes Res Clin Pract 2008;79:518-522 [PMID: 18006105 DOI: 10.1016/j.diabres.2007.10.012]
11. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48:634-642 [PMID: 15747110 DOI: 10.1007/s00125-005-1682-x]
12. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-497 [PMID: 22253363 DOI: 10.1001/jama.2012.39]
13. Masters RK, Reither EN, Powers DA, Yang YC, Burger AE, Link BG. The impact of obesity on US mortality levels: the importance of age and cohort factors in population estimates. Am J Public Health 2013;103:1895-1901 [PMID: 23948004 DOI: 10.2105/AJPH.2013.301379]
14. Ishii S, Tanaka T, Akishita M, Ouchi Y, Tuji T, Iijima K. Metabolic syndrome, sarcopenia and role of sex and age: cross-sectional analysis of Kashiwa cohort study. PLoS One 2014;9:e112718 [PMID: 25405866 DOI: 10.1371/journal.pone.0112718]
15. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middleaged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124-131 [PMID: 20858492 DOI: 10.1053/j.gastro.2010.09.038]
16. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-538 [PMID: 16879891 DOI: 10.1016/j.jhep. 2006.05.013]
17. Bose SK, Ray R. Hepatitis C virus infection and insulin resistance. World J Diabetes 2014;5:52-58 [PMID: 24567801 DOI: 10.4239/wjd.v5.i1.52]
18. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-1364 [PMID: 11391523 DOI: 10.1053/jhep. 2001.24432]
19. Peng D, Han Y, Ding H, Wei L. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J Gastroenterol Hepatol 2008;23:1082-1088 [PMID: 18707599 DOI: 10.1111/j.1440-1746.2008.05478.x]
20. Wang CC, Hsu CS, Liu CJ, Kao JH, Chen DS. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol 2008;23:779-782 [PMID: 18028349 DOI: 10.1038/sj.ijo.0803204]
21. Jan CF, Chen CJ, Chiu YH, Chen LS, Wu HM, Huang CC, Yen MF, Chen TH. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10). Int J Obes (Lond) 2006;30:794-799 [PMID: 16404404 DOI: 10.1111/j.1440-1746.2007.05216.x]
22. Day CP, James OF. Steatohepatitis: a tale of two 'hits'? Gastroenterology 1998;114:842-845 [PMID: 9547102 DOI: 10.1016/S0016-5085 (98) 70599-2]
23. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010;52:1836-1846 [PMID: 21038418 DOI: 10.1002/hep. 24001]
24. Moriya K, Todoroki T, Tsutsumi T, Fujie H, Shintani Y, Miyoshi H, Ishibashi K, Takayama T, Makuuchi M, Watanabe K, Miyamura T, Kimura S, Koike K. Increase in the concentration of carbon 18 monounsaturated fatty acids in the liver with hepatitis C: analysis in transgenic mice and humans. Biochem Biophys Res Commun 2001;281:1207-1212 [PMID: 11243863 DOI: 10.1006/bbrc.2001.4523]
25. Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, Chan HL, Irving WL, Sheridan D, Abate ML, Adams LA, Mangia A, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W, Powell E, Nattermann J, Riordan S, McLeod D, Armstrong NJ, Douglas MW, Liddle C, Booth DR, George J, Ahlenstiel G. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun 2015;6:6422 [PMID: 25740255 DOI: 10.1038/ncomms7422]
26. Gonzalez-Reimers E, Quintero-Platt G, Rodriguez-Gaspar M, Aleman-Valls R, Perez-Hernandez O, Santolaria-Fernandez F. Liver steatosis in hepatitis C patients. World J Hepatol 2015;7:1337-1346 [PMID: 26052379 DOI: 10.4254/wjh.v7.i10.1337]
27. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 2007;46:999-1008 [PMID: 17188392 DOI: 10.1016/j.jhep. 2006.10.019]
28. Lima-Cabello E, García-Mediavilla MV, Miquilena-Colina ME, Vargas-Castrillón J, Lozano-Rodríguez T, Fernández-Bermejo M, Olcoz JL, González-Gallego J, García-Monzón C, Sánchez-Campos S. Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clin Sci (Lond) 2011;120:239-250 [PMID: 20929443 DOI: 10.1042/CS20100387]
29. Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, Gopal P, Waljee AK. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol 2014;109:325-334 [PMID: 24445574 DOI: 10.1038/ajg.2013.476]
30. Nakamura M, Kanda T, Nakamoto S, Miyamura T, Jiang X, Wu S, Yokosuka O. No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV. PLoS One 2013;8:e81312 [PMID: 24349054 DOI: 10.1371/journal.pone.0081312]
31. Kim JY, Song EH, Lee HJ, Oh YK, Choi KH, Yu DY, Park SI, Seong JK, Kim WH. HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways. J Mol Biol 2010;397:917-931 [PMID: 20156456 DOI: 10.1016/j.jmb.2010.02.016]
32. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438 [PMID: 7382552]
33. Nagaya T, Tanaka N, Suzuki T, Sano K, Horiuchi A, Komatsu M, Nakajima T, Nishizawa T, Joshita S, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Nakayama J, Tanaka E, Aoyama T. Down-regulation of SREBP-1c is associated with the development of burned-out NASH. J Hepatol 2010;53:724-731 [PMID: 20655124 DOI: 10.1016/j.jhep. 2010.04.033]
34. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321 [PMID: 15915461 DOI: 10.1002/hep. 20701]
35. Brandman D, Pingitore A, Lai JC, Roberts JP, Ferrell L, Bass NM, Terrault NA. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl 2011;17:1380-1386 [PMID: 21770018 DOI: 10.1002/lt.22389]
36. Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Unalp A. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with nonalcoholic fatty liver disease. J Hepatol 2008;48:829-834 [PMID: 18321606 DOI: 10.1016/j.jhep. 2008.01.016]
37. Zubair A, Jamal S, Mubarik A. Morphometric analysis of hepatic steatosis in chronic hepatitis C infection. Saudi J Gastroenterol 2009;15:11-14 [PMID: 19568548 DOI: 10.4103/1319-3767.45047]
38. Basaranoglu M, Basaranoglu G. Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol 2011;17:4055-4062 [PMID: 22039318 DOI: 10.3748/wjg.v17.i36.4055]
39. Fraquelli M, Rigamonti C, Casazza G, Donato MF, Ronchi G, Conte D, Rumi M, Lampertico P, Colombo M. Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. J Hepatol 2011;54:621-628 [PMID: 21146243 DOI: 10.1016/j.jhep. 2010.07.017]
40. Demir K, Akyuz F, Ozdil S, Aksoy N, Kaymakoglu S, Poturoglu S, Akyüz U, Besisik F, Boztas G, Mungan Z, Cevikbas U, Cakaloglu Y, Okten A. What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis? Ann Hepatol 2007;6:92-96 [PMID: 17519831]
41. Kamada Y, Fujii H, Fujii H, Sawai Y, Doi Y, Uozumi N, Mizutani K, Akita M, Sato M, Kida S, Kinoshita N, Maruyama N, Yakushijin T, Miyazaki M, Ezaki H, Hiramatsu N, Yoshida Y, Kiso S, Imai Y, Kawada N, Takehara T, Miyoshi E. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. Proteomics Clin Appl 2013;7:648-656 [PMID: 23775887 DOI: 10.1002/prca.201200137]
42. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallée M, Heaton S, Conrad A, Pockros PJ, McHutchison JG. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004;40:484-490 [PMID: 15123364 DOI: 10.1016/j.jhep. 2003.11.004]
43. Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, Zeuzem S, Schalm SW, Verheij-Hart E, Negro F, Missale G, Neumann AU, Hellstrand K. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat 2007;14:29-35 [PMID: 17212641 DOI: 10.1111/j.1365-2893.2006.00777.x]
44. Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, De Nicola S, Degasperi E, Grancini V, Colombo M. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology 2012;56:1681-1687 [PMID: 22619107 DOI: 10.1002/hep. 25867]
45. Cindoruk M, Karakan T, Unal S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gastroenterol 2007;41:513-517 [PMID: 17450036 DOI: 10.1097/01.mcg.0000225586.78330.60]
46. Ateş F, Yalníz M, Alan S. Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B. World J Gastroenterol 2011;17:4517-4522 [PMID: 22110283 DOI: 10.3748/wjg.v17.i40.4517]
47. Jin X, Chen YP, Yang YD, Li YM, Zheng L, Xu CQ. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One 2012;7:e34198 [PMID: 22479562 DOI: 10.1371/journal.pone.0034198]
48. Tennant BC, Baldwin BH, Graham LA, Ascenzi MA, Hornbuckle WE, Rowland PH, Tochkov IA, Yeager AE, Erb HN, Colacino JM, Lopez C, Engelhardt JA, Bowsher RR, Richardson FC, Lewis W, Cote PJ, Korba BE, Gerin JL. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 1998;28:179-191 [PMID: 9657111 DOI: 10.1002/hep. 510280124]
49. Baker DE. Adefovir dipivoxil: focus on its use in the treatment of chronic hepatitis B. Rev Gastroenterol Disord 2005;5:89-100 [PMID: 15976740]
50. Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, McHutchison J, Subramanian M, Sampson M, Naggie S, Patel K, Remaley AT, Masur H, Kottilil S. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology 2015;61:790-801 [PMID: 25203718 DOI: 10.1002/hep. 27424]
51. Banerjee S, Saito K, Ait-Goughoulte M, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J Virol 2008;82:2606-2612 [PMID: 18160431 DOI: 10.1128/JVI.01672-07]
52. Sheridan DA, Neely RD, Bassendine MF. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs). Clin Res Hepatol Gastroenterol 2013;37:10-16 [PMID: 22959093 DOI: 10.1016/j.clinre.2012.07.002]
53. Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ, Neely RD. Lipids and HCV. Semin Immunopathol 2013;35:87-100 [PMID: 23111699 DOI: 10.1007/s00281-012-0356-2]
54. Bridge SH, Sheridan DA, Felmlee DJ, Crossey MM, Fenwick FI, Lanyon CV, Dubuc G, Seidah NG, Davignon J, Thomas HC, Taylor-Robinson SD, Toms GL, Neely RD, Bassendine MF. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism. J Hepatol 2015;62:763-770 [PMID: 25463543 DOI: 10.1016/j.jhep. 2014.11.016]
55. Bassendine MF, Sheridan DA, Felmlee DJ, Bridge SH, Toms GL, Neely RD. HCV and the hepatic lipid pathway as a potential treatment target. J Hepatol 2011;55:1428-1440 [PMID: 21718665 DOI: 10.1016/j.jhep. 2011.06.004]
56. Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int 2010;4:548-561 [PMID: 21063477 DOI: 10.1007/s12072-010-9193-3]